Affymax Inc.

Palo Alto, Calif. • 650-812-8700 •

Exchange and Ticker: Nasdaq: AFFY

Filing Range: 3.5M shares @ $22.0 to $24.0

Offering Price: $25.0

Close on First Day: $33.88

Offering Size: $92.5M

Shares Outstanding: 14.86M

Underwriter: Morgan Stanley

Co-managers: RBC Capital Markets/Thomas Weisel Partners/ Cowen & Co.

Company Counsel: Cooley Godward LLP

Manager Counsel: Davis Polk & Wardwell

Auditor: Pricewaterhouse Coopers LLP

Market Capitalization on 31/12/06: $506.0 M

Close price at current month end: $34.04


Operates as a drug discovery and product development company that develops peptide drugs for the treatment of various blood, cancer and kidney diseases. Hematide, Affymax’s product, is designed to treat anemia associated with chronic kidney disease and cancer. Competitors include Ortho Biotech Products, Roche, FibroGen and Johnson & Johnson.


Apax Partners Worldwide, Bear Stearns Health Innoventures, Bessemer Venture Partners, Diamond Capital, JAFCO Co., Merlin Biosciences, MPM Capital, Sprout Group

Source: Thomson Financial